HOUSE BILL No. 1232

DIGEST OF INTRODUCED BILL

Citations Affected: IC 16-18-2; IC 16-46.5; IC 34-30-2-83.9.

Synopsis: Interstate compact on curing diseases. Establishes the solemn covenant of the states to award prizes for curing disease compact. Establishes responsibilities and duties within the compact. Provides for immunity for members, officers, executive director, employees, and representatives of the solemn covenant of states commission.

Effective: July 1, 2020.

Baird

January 13, 2020, read first time and referred to Statutory Committee on Interstate and International Cooperation.



Introduced

Second Regular Session of the 121st General Assembly (2020)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2019 Regular Session of the General Assembly.

HOUSE BILL No. 1232

A BILL FOR AN ACT to amend the Indiana Code concerning health.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 16-18-2-66.3 IS ADDED TO THE INDIANA
2	CODE AS A NEW SECTION TO READ AS FOLLOWS
3	[EFFECTIVE JULY 1, 2020]: Sec. 66.3. "Compact", for purposes of
4	IC 16-46.5, has the meaning set forth in IC 16-46.5-1-2.
5	SECTION 2. IC 16-18-2-66.4 IS ADDED TO THE INDIANA
6	CODE AS A NEW SECTION TO READ AS FOLLOWS
7	[EFFECTIVE JULY 1, 2020]: Sec. 66.4. "Compacting state", for
8	purposes of IC 16-46.5, has the meaning set forth in IC 16-46.5-1-3.
9	SECTION 3. IC 16-18-2-249.8 IS ADDED TO THE INDIANA
10	CODE AS A NEW SECTION TO READ AS FOLLOWS
11	[EFFECTIVE JULY 1, 2020]: Sec. 249.8. "Non-compacting state",
12	for purposes of IC 16-46.5, has the meaning set forth in
13	IC 16-46.5-1-4.
14	SECTION 4. IC 16-18-2-298.6 IS ADDED TO THE INDIANA
15	CODE AS A NEW SECTION TO READ AS FOLLOWS
16	[EFFECTIVE JULY 1, 2020]: Sec. 298.6. "Public health expenses",
17	for purposes of IC 16-46.5, has the meaning set forth in



2020

1 IC 16-46.5-1-5. 2 SECTION 5. IC 16-18-2-338.4 IS ADDED TO THE INDIANA 3 CODE AS A NEW SECTION TO READ AS FOLLOWS 4 [EFFECTIVE JULY 1, 2020]: Sec. 338.4. "State", for purposes of 5 IC 16-46.5, has the meaning set forth in IC 16-46.5-1-6. 6 SECTION 6. IC 16-46.5 IS ADDED TO THE INDIANA CODE AS 7 A NEW ARTICLE TO READ AS FOLLOWS [EFFECTIVE JULY 1, 8 2020]: 9 **ARTICLE 46.5. SOLEMN COVENANT OF THE STATES TO** 10 AWARD PRIZES FOR CURING DISEASES COMPACT 11 **Chapter 1. Definitions** 12 Sec. 1. The definitions in this chapter apply to this article. 13 Sec. 2. "Compact" means the solemn covenant of the states to 14 award prizes for curing diseases enacted in this article. 15 Sec. 3. "Compacting state" means either of the following: 16 (1) Any state that has enacted the compact and which has not 17 withdrawn or been suspended as described in IC 16-46.5-14. 18 (2) The federal government in accordance with the 19 commission's bylaws. 20 Sec. 4. "Noncompacting state" means any state or the federal 21 government, if the state or federal government is not at the time a 22 compacting state. 23 Sec. 5. "Public health expenses" means the amount of all costs 24 paid by taxpayers in a specified geographic area relating to a 25 particular disease. 26 Sec. 6. "State" means any state, district, or territory of the 27 United States of America. 28 Chapter 2. Establishment of the Commission; Membership 29 Sec. 1. Upon the enactment of the compact by six (6) states, the 30 compacting states shall establish the solemn covenant of states 31 commission. 32 Sec. 2. The commission is a body corporate and politic and an 33 instrumentality of each of the compacting states and is solely 34 responsible for the commission's liabilities, except as otherwise 35 specifically provided in the compact. 36 Sec. 3. Each compacting state shall be represented by one (1) 37 member as selected by the compacting state. Each compacting state 38 shall: 39 (1) determine the compacting state's member qualifications 40 and period of service; and 41 (2) be responsible for any action to remove or suspend the 42 state's member or to fill the member's position if the position



1	becomes vacant.
2	Nothing in the compact shall be construed to affect a compacting
3	state's authority regarding the qualification, selection, or service
4	of the compacting state's own member.
5	Chapter 3. Powers of the Commission
6	Sec. 1. The commission shall have the following authority and
7	power:
8	(1) To adopt bylaws and rules as described in IC 16-46.5-5
9	and IC 16-46.5-6. The bylaws and rules shall have the force
10	and effect of law and shall be binding in the compacting states
11	to the extent and in the manner provided in the compact.
12	(2) To receive and review in an expeditious manner
13	treatments and therapeutic protocols for the cure of disease
14	submitted to the commission and to award prizes for
15	submissions that meet the commission's standards for a
16	successful cure treatment or therapeutic protocol.
17	(3) To make widely available a cure treatment or therapeutic
18	protocol upon a prize winner claiming a prize and
19	transferring any intellectual property necessary for the
20	manufacture and distribution of the cure in accordance with
21	section IC 16-46.5-6, including by arranging or contracting
22	for the:
23	(A) manufacturing;
24	(B) production; or
25	(C) provision of any drug, serum, or other substance,
26	device, or process;
27	provided that the commission does not market the cure or
28	conduct any other activity regarding the cure not specifically
29	authorized in the compact.
30	(4) To establish a selling price for the cure that shall be not
31	more than the expenses for:
32	(A) the cure's manufacturing;
33	(B) the cure's distribution;
34	(C) the cure's licensing; and
35	(D) either:
36	(i) any other necessary governmental requirements for
37	compacting states; or
38	(ii) those expenses plus any royalty fees, for
39	noncompacting states.
40	The price shall not include the expenses of any other activities.
41	(5) In noncompacting states and foreign countries, to establish
42	and collect royalty fees imposed on manufacturers, producers,



1 and providers of any: 2 (A) drug; 3 (B) serum or other substance; 4 (C) device; or 5 (D) process; 6 used for a cure may be added to the sales price of the cure 7 pursuant to subdivision (4) if the royalty fees shall 8 cumulatively be not more than the estimated five (5) year 9 savings in public health expenses for that state or country, as 10 calculated by actuaries employed or contracted by the 11 commission. 12 (6) To do the following regarding the collected royalty fees: 13 (A) Pay or reimburse expenses related to the payment of a 14 prize, including: 15 (i) employing or contracting actuaries to calculate 16 annual taxpayer savings amounts in compacting states in 17 accordance with IC 16-46.5-6-3(7)(C); and 18 (ii) payment of interest and other expenses related to a 19 loan obtained in accordance with IC 16-46.5-6-3(7)(F). 20 (B) Annually disburse any amounts remaining after 21 making payments or reimbursements under clause (A) as 22 refunds to compacting states based on the percent of the 23 state's prize obligation in relation to the total obligation 24 amount of all compacting states. 25 (7) To bring and prosecute legal proceedings or actions in the 26 commission's name. 27 (8) To issue subpoenas requiring the attendance and 28 testimony of witnesses and the production of evidence. 29 (9) To establish and maintain offices. 30 (10) To borrow, accept, or contract for personnel services, 31 including personnel services from employees of a compacting 32 state. 33 (11) To hire employees, professionals, or specialists, and elect 34 or appoint officers, and to: 35 (A) fix compensation; 36 (B) define duties: 37 (C) give appropriate authority to carry out the purposes of 38 the compact; 39 (D) determine qualifications; and 40 (E) establish the commission's personnel policies and 41 programs concerning conflicts of interest, rates of 42 compensation, and qualifications of personnel.



1	(12) To accept any and all appropriate donations and grants
2	of money, equipment, supplies, materials, and services, and to
3	receive, utilize, and dispose of the same, provided that at all
4	times the commission shall strive to avoid any appearance of
5	impropriety.
6	(13) To:
7	(A) lease;
8	(B) purchase;
9	(C) accept appropriate gifts or donations of;
10	(D) own;
11	(E) hold;
12	(F) improve; or
13	(G) use;
14	any property, real, personal, or mixed, provided, that at all
15	times the commission shall strive to avoid any appearance of
16	impropriety.
17	(14) To sell, convey, mortgage, pledge, lease, exchange,
18	abandon, or otherwise dispose of any property, real, personal,
19	or mixed.
20	(15) To monitor compacting states for compliance with the
20	commission's bylaws and rules.
21	(16) To enforce compliance by compacting states with the
23	commission's bylaws and rules.
23	(17) To provide for dispute resolution among compacting
25	states or between the commission and those who submit
26	treatments and therapeutic protocols for the cure of disease
20	for consideration.
28	(18) To establish a budget and make expenditures.
29	(19) To borrow money.
30	(20) To appoint committees, including management,
31	legislative, and advisory committees comprised of members,
32	state legislators or a state legislator's representatives, medical
33	professionals, and other interested persons as may be
34	designated by the commission.
35	(21) To establish annual membership dues for compacting
36	states, which shall be used for daily expenses of the
37	commission and not for interest or prize payments.
38	(22) To adopt and use a corporate seal.
39	(22) To adopt and use a corporate seal. (23) To perform such other functions as may be necessary or
40	appropriate to achieve the purposes of this compact.
40 41	Chapter 4. Meetings and Voting
41 42	
42	Sec. 1. The commission shall meet and take such actions as are

1 consistent with the compact, bylaws, and rules. 2 Sec. 2. A majority of the members of the commission shall 3 constitute a quorum necessary in order to conduct business or take 4 actions at meetings of the commission. 5 Sec. 3. Each member of the commission shall have the right and 6 power to cast one (1) vote regarding matters determined or actions 7 to be taken by the commission. Each member shall have the right 8 and power to participate in the business and affairs of the 9 commission. 10 Sec. 4. A member shall vote in person or by such other means as 11 provided in the commission's bylaws. The commission's bylaws 12 may provide for members' participation in meetings by telephone 13 or other means of communication. 14 Sec. 5. The commission shall meet at least once during each 15 calendar year. Additional meetings shall be held as set forth in the 16 commission's bylaws. 17 Sec. 6. No decision of the commission concerning the approval 18 of an award for a treatment or therapeutic process for the cure of 19 a disease shall be effective unless two-thirds (2/3) of all members of 20 the commission vote in favor of the decision. 21 Sec. 7. Guidelines and voting requirements for all other 22 decisions of the commission shall be established in the 23 commission's bylaws. 24 **Chapter 5. Bylaws** 25 Sec. 1. The commission's bylaws must include the following: 26 (1) Establish the fiscal year of the commission. 27 (2) Provide reasonable procedures for appointing and electing 28 members, and holding meetings of the management 29 committee. 30 (3) Provide reasonable standards and procedures: 31 (A) for the establishment and meetings of the other 32 committees: 33 (B) governing any general or specific delegation of any 34 authority or function of the commission; and 35 (C) for voting guidelines and procedures for commission 36 decisions. 37 (4) Provide reasonable procedures for calling and conducting 38 meetings of the commission that shall consist of: 39 (A) requiring a quorum to be present; 40 (B) ensuring reasonable advance notice of each meeting; 41 and 42 (C) providing for the right of citizens to attend a meeting



1	
1	with enumerated exception designed to protect the public's
2	interest and the privacy of individuals.
3	(5) Provide a list of matters about which the commission may
4	go into executive session and require that a majority of all
5	members of the commission vote to enter into an executive
6	session. As soon as practicable, the commission shall make
7	public:
8	(A) a copy of the vote to go into executive session, revealing
9	the vote of each member with no proxy votes allowed; and
10	(B) the matter requiring executive session without
11	identifying the actual issues or individuals involved.
12	(6) Establish the titles, duties, authority, and reasonable
13	procedures for the election of the officers of the commission.
14	(7) Provide reasonable standards and procedures for the
15	establishment of the personnel policies and programs of the
16	commission. Notwithstanding any civil service or other
17	similar laws of any compacting state, the commission's bylaws
18	shall exclusively govern the personnel policies and programs
19	of the commission.
20	(8) Allow a mechanism for:
21	(A) the federal government to join as a compacting state;
22	and
23	(B) foreign countries or subdivisions of those countries to
24	join as liaison members by adopting the compact, provided
25	that adopting countries or subdivisions shall not have
26	voting power or the power to bind the commission in any
27	way.
28	(9) Adopt a code of ethics to address permissible and
29	prohibited activities of members and employees.
30	(10) Provide for the maintenance of the commission's books
31	and records.
32	(11) Govern the acceptance of and accounting for donations,
33	annual member dues, and other sources of funding, and
34	establish the proportion of these funds to be allocated to prize
35	amounts for treatments and therapeutic protocols that cure
36	disease.
37	(12) Govern any fundraising efforts in which the commission
38	wishes to engage.
39	(13) Provide a mechanism for winding up the operations of
40	the commission and the equitable disposition of any surplus
41	funds that may exist after the termination of the compact
42	after the payment and reserving of all its debts and



1	obligations.
2	Chapter 6. Rules
3	Sec. 1. The commission shall adopt rules to do the following:
4	(1) Effectively and efficiently achieve the purposes of this
5	compact.
6	(2) Govern the methods, processes, and any other aspect for
7	the:
8	(A) research;
9	(B) creation; and
10	(C) testing;
11	of a treatment, or therapeutic protocol for each disease, for
12	which a prize may be awarded.
13	Sec. 2. (a) The commission shall also adopt rules establishing the
14	criteria for defining and classifying the diseases for which prizes
15	shall be awarded. The commission may define and classify subsets
16	of diseases (for example, tubular carcinoma of the breast).
17	(b) For purposes of section 3(1) and 3(3) of this chapter, a subset
18	of a disease shall be considered one (1) disease. The commission
19	may consult the most recent edition of the international
20	classification of disease as published by the World Health
21	Organization for other definitions agreed to by a two-thirds (2/3)
22	vote of the commission.
23	Sec. 3. The commission shall also adopt rules regarding prizes
24	for curing diseases that establish the following:
25	(1) At least ten (10) major diseases for which to create prizes,
26	and shall be determined based on the following factors:
27	(A) The severity of the disease to a human individual's
28	overall health and well-being.
29	(B) The survival rate or severity of impact of the disease.
30	(C) The public health expenses and treatment expenses for
31	the disease.
32	(2) The criteria a treatment or therapeutic protocol must meet
33	in order to be considered a cure for any of the diseases for
34	which a prize may be awarded, and shall include the following
35	requirements:
36	(A) Approval by the federal Food and Drug
37	Administration or have otherwise obtained legal status for
38	the compact to immediately contract to manufacture and
39	distribute in the United States.
40	(B) Except as provided in section 4 of this chapter, must
41	yield a significant increase in survival concerning the
42	diseases if early death is the usual outcome.



IN 1232-LS 7008/DI 104

1(C) Require less than one (1) year of the treatment or protocol to completely cure the disease.3(3) The procedure for determining the diseases for which to award prizes, that includes:5(A) the option to award prizes for more than ten (10) diseases that meet the above criteria, if agreed to by two-thirds (2/3) vote of the commission; and (B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines, including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the cure bears the burden of proof in demonstrating that the treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or protocol submissions.17(5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5) year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized; every three (3) years by actuaries employed or contracted by the commission.23(A) the most recent estimated total five (5) year savings in subdivision (5) in all of the compacing states; subdivision (5) in all of the compacing states; subdivision (6) in all of the compacing states;34(B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and G G G35(A) Upon acceptance of a cu		
 (3) The procedure for determining the diseases for which to award prizes, that includes: (A) the option to award prizes for more than ten (10) diseases that meet the above criteria, if agreed to by two-thirds (2/3) vote of the commission; and (B) a requirement to update the list every three (3) years. (4) The submission and evaluation procedures and guidelines, including the following: (A) Filing and review procedures. (B) A requirement that the person or entity submitting the cure bears the burden of proof in demonstrating that the treatment or therapeutic protocol meets the above criteria. (C) Limitations preventing public access to treatment or protocol submissions. (5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5) year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized; (A) the most recent estimated total five (5) year savings in public health expenses for the disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	1	(C) Require less than one (1) year of the treatment or
4award prizes, that includes:5(A) the option to award prizes for more than ten (10)6diseases that meet the above criteria, if agreed to by7two-thirds (2/3) vote of the commission; and8(B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in </td <td>2</td> <td>protocol to completely cure the disease.</td>	2	protocol to completely cure the disease.
5(A) the option to award prizes for more than ten (10)6diseases that meet the above criteria, if agreed to by7two-thirds (2/3) vote of the commission; and8(B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that33subdivision (5) in all of the compacting state;34(B) amounts donated by charities, individuals, and any35other enti	3	(3) The procedure for determining the diseases for which to
6diseases that meet the above criteria, if agreed to by7two-thirds (2/3) vote of the commission; and8(B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or thrapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that31(A) the most recent estimated total five (5) year savings in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distr		award prizes, that includes:
7two-thirds (2/3) vote of the commission; and8(B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize		(A) the option to award prizes for more than ten (10)
8(B) a requirement to update the list every three (3) years.9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other facto	6	diseases that meet the above criteria, if agreed to by
9(4) The submission and evaluation procedures and guidelines,10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and33(C) any other factors that the commission deems34(B) upon acceptance of a cure, the prize winner shall35the following requirements:34		two-thirds (2/3) vote of the commission; and
10including the following:11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the13cure bears the burden of proof in demonstrating that the14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that31(A) the most recent estimated total five (5) year savings in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and37(C) any other factors that the commission deems38(7) The prize distribution procedures and guidelines that39(A) Upon acceptance of a cure, the prize winner shall41	8	(B) a requirement to update the list every three (3) years.
11(A) Filing and review procedures.12(B) A requirement that the person or entity submitting the cure bears the burden of proof in demonstrating that the treatment or therapeutic protocol meets the above criteria.13(C) Limitations preventing public access to treatment or protocol submissions.17(5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5)18year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized;27every three (3) years by actuaries employed or contracted by the commission.29(6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate.38(7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related	9	(4) The submission and evaluation procedures and guidelines,
12(B) A requirement that the person or entity submitting the cure bears the burden of proof in demonstrating that the treatment or therapeutic protocol meets the above criteria. (C) Limitations preventing public access to treatment or protocol submissions.17(5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5) year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized; every three (3) years by actuaries employed or contracted by the commission.29(6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate.31(A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related	10	including the following:
13cure bears the burden of proof in demonstrating that the treatment or therapeutic protocol meets the above criteria. (C) Limitations preventing public access to treatment or protocol submissions.17(5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5) year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized; every three (3) years by actuaries employed or contracted by the commission.29(6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate.31(A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related	11	(A) Filing and review procedures.
14treatment or therapeutic protocol meets the above criteria.15(C) Limitations preventing public access to treatment or16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	12	(B) A requirement that the person or entity submitting the
15(C) Limitations preventing public access to treatment or protocol submissions.17(5) The estimated five (5) year public health savings that would result from a cure that shall be equal to the five (5) year public health expenses for each disease in each compacting state, and a procedure to update these expenses every three (3) years in conjunction with the requirements in subdivision (3). The estimated five (5) year public health savings amount shall be: (A) calculated; (B) estimated; and (C) publicized;27every three (3) years by actuaries employed or contracted by the commission.29(6) The prize amount concerning cures for each disease that must be equal to:31(A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate.38(7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related	13	cure bears the burden of proof in demonstrating that the
16protocol submissions.17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	14	treatment or therapeutic protocol meets the above criteria.
17(5) The estimated five (5) year public health savings that18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	15	(C) Limitations preventing public access to treatment or
18would result from a cure that shall be equal to the five (5)19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	16	protocol submissions.
19year public health expenses for each disease in each20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	17	(5) The estimated five (5) year public health savings that
20compacting state, and a procedure to update these expenses21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	18	would result from a cure that shall be equal to the five (5)
21every three (3) years in conjunction with the requirements in22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	19	year public health expenses for each disease in each
22subdivision (3). The estimated five (5) year public health23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	20	compacting state, and a procedure to update these expenses
23savings amount shall be:24(A) calculated;25(B) estimated; and26(C) publicized;27every three (3) years by actuaries employed or contracted by28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	21	every three (3) years in conjunction with the requirements in
 (A) calculated; (B) estimated; and (C) publicized; every three (3) years by actuaries employed or contracted by the commission. (6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	22	subdivision (3). The estimated five (5) year public health
 (B) estimated; and (C) publicized; every three (3) years by actuaries employed or contracted by the commission. (6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	23	savings amount shall be:
 (C) publicized; every three (3) years by actuaries employed or contracted by the commission. (6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	24	(A) calculated;
 every three (3) years by actuaries employed or contracted by the commission. (6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	25	(B) estimated; and
28the commission.29(6) The prize amount concerning cures for each disease that30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	26	(C) publicized;
 (6) The prize amount concerning cures for each disease that must be equal to: (A) the most recent estimated total five (5) year savings in public health expenses for the disease as calculated in subdivision (5) in all of the compacting states; (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	27	every three (3) years by actuaries employed or contracted by
30must be equal to:31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	28	the commission.
31(A) the most recent estimated total five (5) year savings in32public health expenses for the disease as calculated in33subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related	29	(6) The prize amount concerning cures for each disease that
32public health expenses for the disease as calculated in subdivision (5) in all of the compacting states;34(B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate.36(C) any other factors that the commission deems appropriate.38(7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related	30	must be equal to:
 33 subdivision (5) in all of the compacting states; 34 (B) amounts donated by charities, individuals, and any 35 other entities intended for the prize under this article; and 36 (C) any other factors that the commission deems 37 appropriate. 38 (7) The prize distribution procedures and guidelines that 39 include the following requirements: 40 (A) Upon acceptance of a cure, the prize winner shall 41 transfer to the commission the patent and all related 	31	(A) the most recent estimated total five (5) year savings in
 (B) amounts donated by charities, individuals, and any other entities intended for the prize under this article; and (C) any other factors that the commission deems appropriate. (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 	32	public health expenses for the disease as calculated in
35other entities intended for the prize under this article; and36(C) any other factors that the commission deems37appropriate.38(7) The prize distribution procedures and guidelines that39include the following requirements:40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related		
 36 (C) any other factors that the commission deems 37 appropriate. 38 (7) The prize distribution procedures and guidelines that 39 include the following requirements: 40 (A) Upon acceptance of a cure, the prize winner shall 41 transfer to the commission the patent and all related 	34	(B) amounts donated by charities, individuals, and any
 37 appropriate. 38 (7) The prize distribution procedures and guidelines that 39 include the following requirements: 40 (A) Upon acceptance of a cure, the prize winner shall 41 transfer to the commission the patent and all related 	35	other entities intended for the prize under this article; and
 (7) The prize distribution procedures and guidelines that include the following requirements: (A) Upon acceptance of a cure, the prize winner shall transfer to the commission the patent and all related 		(C) any other factors that the commission deems
 39 include the following requirements: 40 (A) Upon acceptance of a cure, the prize winner shall 41 transfer to the commission the patent and all related 		appropriate.
40(A) Upon acceptance of a cure, the prize winner shall41transfer to the commission the patent and all related		
41 transfer to the commission the patent and all related		
1		
42 intellectual property for the manufacture and distribution		•
	42	intellectual property for the manufacture and distribution

IN 1232-LS 7008/DI 104

1of the treatment or therapeutic protocol in exchang2the prize, except in the case that the prize mor3considered by the commission to be too low, and the prize	ney is that a
	that a
3 considered by the commission to be too low, and t	
•	
4 prize will be awarded only to the first person or entit	•
5 submits a successful cure for a disease for which a	prize
6 may be awarded.	
7 (B) Donation amounts intended for the prize shall be	-
8 in a separate, interest bearing account maintained b	•
9 commission and shall be the only account in which	prize
10 money is kept.	
11 (C) Each compacting state shall meet the following:	
12 (i) Have the responsibility to pay annually	
13 compacting state's actual one (1) year savings in p	
14 health expenses for the particular disease for wh	iich a
15 cure has been accepted.	
16 (ii) Make the annual payment until the compacting	
17 has fulfilled the compacting state's prize responsibi	•
18 established in subdivision (6). Each compacting s	
19 payment responsibility begins one (1) year after the	e date
20 the cure becomes widely available.	
21 The commission shall employ or contract with actual	
22 calculate each state's actual one (1) year savings in p	
23 health expenses at the end of each year to determine	e each
24 state's responsibility for the succeeding year.	
25 (D) Allow compacting states to meet prize responsib	
26 by any method, including the issuance of bonds or	
27 obligations with the principal and interest of those l	
28 or obligations to be repaid only from revenue derived	
29 estimated public health expense savings from a cur	
30 disease. If the compacting state does not make the rev	
31 available to repay some or all of the revenue bon	
32 obligations issued, the owners or holders of those bor	
33 obligations have no right to have excises or taxes lev	ried to
34 pay the principal or interest on the bonds or obliga	
35 The revenue bonds and obligations are not a debt	of the
36 issuing compacting state.	
37 (E) Allow a compacting state to issue bonds or other	
38that are general obligations, under which the full fait	
39 credit, revenue, and taxing power of the state is pleda	
40 pay the principal and interest under those obligations	
41 if authorized by the compacting state's constitution	
42 constitutional authorization is not required, by othe	er law



1 of the compacting state. 2 (F) Upon acceptance of a cure, require the commission to 3 obtain a loan from a financial institution in an amount 4 equal to the most recently calculated total estimated five 5 (5) year public health expenses for the disease in all 6 compacting states, in accordance with subdivision (6). The 7 commission reserves the right to continuously evaluate the 8 cure in the interim and rescind a prize offer if the 9 commission finds that the cure no longer meets the 10 commission's criteria. 11 Sec. 4. The commission may award a prize for a treatment or 12 therapeutic protocol that yields a survival rate that is less than 13 what is established in the cure criteria through at least five (5) 14 years after the treatment or protocol has ended. In this case, the 15 prize amount awarded for that treatment or therapeutic protocol 16 shall be reduced from the prize amount originally determined by 17 the commission for a cure for that disease. The reduction shall be 18 in proportion to the survival rate yielded by the treatment or 19 protocol as compared to the survival rate established in the cure 20 criteria. 21 Sec. 5. The commission also shall adopt rules that do the 22 following: 23 (1) Establish the following regarding commission records: 24 (A) Conditions and procedures for public inspection and 25 copying of its information and official records, except any 26 information and records involving the privacy of 27 individuals or that would otherwise violate privacy laws 28 under federal law and the laws of the compacting states. 29 (B) Procedures for sharing with federal and state agencies, 30 including law enforcement agencies, records and 31 information otherwise exempt from disclosure. 32 (C) Guidelines for entering into agreements with federal 33 and state agencies to receive or exchange information or 34 records subject to nondisclosure and confidentiality 35 provisions. 36 (2) Provide a process for commission review of submitted 37 treatments and therapeutic protocols for curing diseases that 38 includes the following: 39 (A) An opportunity for an appeal, not later than thirty (30) 40 days after a rejection of a treatment or protocol for prize 41 consideration, to a review panel established under the 42 commission's dispute resolution process.



1 (B) Commission monitoring and review of treatment and 2 protocol effectiveness consistent with the cure criteria 3 established by the commission for the particular disease. 4 (3) Establish a dispute resolution process to resolve disputes 5 or other issues under the compact that may arise between two 6 (2) or more compacting states or between the commission and 7 individuals or entities who submit treatments and therapeutic 8 protocols to cure diseases. The dispute resolution process shall 9 provide for: 10 (A) administrative review by a review panel appointed by 11 the commission; 12 (B) judicial review of decisions issued after an 13 administrative review; and 14 (C) qualifications to be appointed to a panel, due process 15 requirements, including notice and hearing procedures, 16 and any other procedure, requirement, or standard 17 necessary to provide adequate dispute resolution. 18 (4) Establish and impose annual member dues on compacting 19 states that shall be calculated based on the percentage of each 20 compacting state's population in relation to the population of 21 all the compacting states. 22 Sec. 6. (a) Recognizing that the goal of the compact is to pool the 23 potential savings of as many states and countries as possible to 24 generate sufficient financial incentive to develop a cure of many of 25 the world's most devastating diseases, the compact will respect the 26 laws of each of these United States by adopting rules that establish 27 ethical standards for research that shall be followed in order for a 28 prize to be claimed. 29 (b) The compact, in the rules, shall establish a common set of 30 ethical standards that embodies the laws and restrictions in each 31 of the states so that to be eligible for claiming a prize the entity 32 submitting a cure must not have violated any of the ethical 33 standards in any one (1) of the fifty (50) states, whether the states 34 have joined the compact or not. The compact will publish these 35 common ethical standards along with specific criteria for a cure 36 for each of the diseases the compact has targeted. 37 (c) So long as a researcher follows the common ethical 38 standards in effect at the time the research is done, an entity 39 presenting a cure will be deemed to have followed the standards. 40 (d) On or before January 1 of each year, the compact shall 41 review all state laws to determine if additional ethical standards 42 have been enacted by any of the fifty (50) states and the federal



2020

1 government. Any changes to the common ethical standards rules 2 based on new state laws shall be adopted and published by the 3 compact, but shall not take effect in cure criteria for a period of 4 three (3) years to allow for sufficient notice to researchers. 5 Sec. 7. All rules may be amended as the commission sees 6 necessary. 7 Sec. 8. All rules shall be adopted pursuant to a rulemaking 8 process that conforms to the model state administrative procedure 9 act of 1981 by the uniform law commissioners, as amended, as may 10 be appropriate to the operations of the commission. 11 Sec. 9. If the commission exercises the commission's rulemaking 12 authority in a manner that is beyond the scope of the purpose of 13 this compact, or the powers granted under the compact, then the 14 rule shall be invalid and have no force and effect. 15 **Chapter 7. Committees** 16 Sec. 1. (a) The commission may establish a management 17 committee comprised of not more than fourteen (14) members 18 when twenty-six (26) states enact the compact. 19 (b) The committee shall consist of those members representing 20 compacting states whose total public health expenses of all of the 21 established diseases are the highest. 22 (c) The committee shall have the authority and duties as may be 23 set forth in the commission's bylaws and rules, including the 24 following: 25 (1) Managing authority over the day-to-day affairs of the 26 commission in a manner consistent with the commission's 27 bylaws and rules and the purposes of the compact. 28 (2) Overseeing the offices of the commission. 29 (3) Planning, implementing, and coordinating 30 communications and activities with state, federal, and local 31 government organizations in order to advance the goals of the 32 compact. 33 (d) The commission annually shall elect officers for the 34 committee, with each having the authority and duties as may be 35 specified in the commission's bylaws and rules. 36 (e) The management committee, subject to commission 37 approval, may appoint or retain an executive director for a period, 38 upon such terms and conditions, and for the compensation as the 39 committee determines. The executive director shall serve as 40 secretary to the commission, but shall not be a member of the commission. The executive director shall hire and supervise such 41

42 other staff as may be authorized by the committee.



1 Sec. 2. (a) The commission may appoint advisory committees to 2 monitor all operations related to the purposes of the compact and 3 make recommendations to the commission. The manner of 4 selection and term of any committee member shall be as set forth 5 in the commission's bylaws and rules. 6 (b) The commission shall consult with an advisory committee, 7 to the extent required by the commission's bylaws or rules, before 8 doing any of the following: 9 (1) Approving cure criteria. 10 (2) Amending, enacting, or repealing any bylaw or rule. 11 (3) Adopting the commission's annual budget. 12 (4) Addressing any other significant matter or taking any 13 other significant action. 14 **Chapter 8. Finance** 15 Sec. 1. (a) The commission annually shall establish a budget to 16 pay or provide for the payment of its reasonable expenses. 17 (b) To fund the cost of initial operations, the commission may 18 accept contributions and other forms of funding from the 19 compacting states and other sources. Contributions and other 20 forms of funding from other sources shall be of such a nature that 21 the independence of the commission concerning the performance 22 of its duties shall not be compromised. 23 Sec. 2. The commission shall be exempt from all taxation in and 24 by the compacting states. 25 Sec. 3. (a) The commission shall keep complete and accurate 26 accounts of all of its internal receipts, including grants and 27 donations, and disbursements of all funds under its control. The 28 internal financial accounts of the commission shall be subject to the 29 accounting procedures established under the commission's bylaws 30 or rules. 31 (b) The financial accounts and reports, including the system of 32 internal controls and procedures of the commission, shall be 33 audited annually by an independent certified public accountant. 34 Upon the determination of the commission, but not less frequently 35 than every three (3) years, the review of the independent auditor 36 shall include a management and performance audit of the 37 commission. 38 (c) The commission shall make an annual report to the 39 governors and legislatures of the compacting states, which shall 40 include a report of the independent audit. (d) The commission's internal accounts shall not be confidential 41 42 and such materials may be shared with any compacting state upon

request, provided, however, that any work papers related to any internal or independent audit and any information subject to the compacting states' privacy laws shall remain confidential.

Sec. 4. No compacting state shall have any claim or ownership of any property held by or vested in the commission or to any commission funds held pursuant to the provisions of the compact. Chapter 9. Records

Sec. 1. (a) Except as to privileged records, data, and information, the laws of any compacting state pertaining to confidentiality or nondisclosure shall not relieve any member of the duty to disclose any relevant records, data, or information to the commission.

(b) Disclosure to the commission shall not be deemed to waive
or otherwise affect any confidentiality requirement. Except as
otherwise expressly provided in the compact, the commission shall
not be subject to the compacting state's laws pertaining to
confidentiality and nondisclosure with respect to records, data, and
information in its possession.

Sec. 2. Confidential information of the commission shall remain
 confidential after the information is provided to any member. All
 cure submissions received by the commission are confidential.

Chapter 10. Compliance

1

2

3

4

5

6

7

8

9

10

11

12

22

23

24

25

26

27

28

29

34

35

36

37

38

39

40

41

42

Sec. 1. (a) The commission shall notify a compacting state in writing of any noncompliance with commission bylaws and rules.

(b) If a compacting state fails to remedy the compacting state's noncompliance within the time specified in the notice, the compacting state shall be deemed to be in default as set forth in IC 16-46.5-14.

Chapter 11. Venue

Sec. 1. Venue for any judicial proceedings by or against the
 commission shall be brought in the appropriate court of competent
 jurisdiction for the geographical area in which the principal office
 of the commission is located.

Chapter 12. Qualified Immunity, Defense, and Indemnification Sec. 1. The members, officers, executive director, employees, and representatives of the commission shall be immune from suit and liability, either personally or in their official capacity, for any claim for damage to or loss of property or personal injury or other civil liability caused by or arising out of any actual or alleged act, error, or omission that occurred, or that such person had a reasonable basis for believing occurred within the scope of the person's commission employment, duties, or responsibilities.



However, nothing in this section shall be construed to protect any person from suit or liability for any damage, loss, injury, or liability caused by the intentional or willful and wanton misconduct of that person.

Sec. 2. (a) The commission shall defend any member, officer, executive director, employee, or representative of the commission in any civil action seeking to impose liability arising out of any actual or alleged act, error, or omission that occurred within the scope of the person's commission employment, duties, or responsibilities, or that the person had a reasonable basis for believing occurred within the scope of commission employment, duties, or responsibilities.

(b) Nothing in the compact or commission bylaws or rules shall
be construed to prohibit a person from retaining the person's own
counsel, and provided further, that the actual or alleged act, error,
or omission did not result from that person's intentional or willful
and wanton misconduct.

Sec. 3. The commission shall indemnify and hold harmless any 18 19 member, officer, executive director, employee, or representative of 20 the commission for the amount of any settlement or judgment 21 obtained against the person arising out of any actual or alleged act, 22 error, or omission that occurred within the scope of the person's 23 commission employment, duties, or responsibilities, or that such 24 person had a reasonable basis for believing occurred within the 25 scope of commission employment, duties, or responsibilities, 26 provided that the actual or alleged act, error, or omission did not 27 result from the intentional or willful and wanton misconduct of 28 that person.

Chapter 13. Compacting States, Effective Date, and Amendment Sec. 1. Any state is eligible to become a compacting state.

Sec. 2. The compact shall become effective and binding upon legislative enactment of the compact into law by two (2) compacting states. However, the commission shall only be established after six (6) states become compacting states. Thereafter, the compact shall become effective and binding as to any other compacting state upon enactment of the compact into law by that state.

Sec. 3. Amendments to the compact may be proposed by the commission for enactment by the compacting states. No amendment shall become effective and binding until all compacting states enact the amendment into law.

Sec. 4. If funding is requested or required, the legislative



1

2

3

4

5

6

7

8

9

10

11

12

29

30

31

32

33

34

35

36

37

38

39

40

41

42

1 authority of each compacting state shall be responsible for making 2 the appropriations the state determines necessary to pay for the 3 costs of the compact, including annual member dues and prize 4 distributions. 5 Chapter 14. Withdrawal, Default, and Expulsion 6 Sec. 1. (a) Once effective, the compact shall continue in force 7 and remain binding upon each and every compacting state. A 8 compacting state may withdraw from the compact by doing both 9 of the following: 10 (1) Repealing the law enacting the compact in that state. 11 (2) Notifying the commission in writing of the intent to 12 withdraw on a date that is both of the following: 13 (A) At least three (3) years after the date the notice is sent. 14 (B) After the repeal takes effect. 15 (b) The effective date of withdrawal is the date described in 16 subsection (a)(2). 17 (c) The member representing the withdrawing state shall 18 immediately notify the management committee in writing upon the 19 introduction of legislation in that state repealing the compact. If a 20 management committee has not been established, the member shall 21 immediately notify the commission. 22 (d) The commission or management committee, as applicable, 23 shall notify the other compacting states of the introduction of the 24 legislation within ten (10) days of the commission's receipt of the 25 notice. 26 (e) The withdrawing state is responsible for all obligations, 27 duties, and liabilities incurred through the effective date of 28 withdrawal, including any obligations the performance of which 29 extend beyond the effective date of withdrawal. The commission's 30 actions shall continue to be effective and be given full force and 31 effect in the withdrawing state. (f) Reinstatement following a state's withdrawal shall become 32 33 effective upon the effective date of the subsequent enactment of the 34 compact by that state. 35 Sec. 2. (a) If the commission determines that any compacting 36 state has at any time defaulted in the performance of any of the 37 state's obligations or responsibilities under the compact or the 38 commission's bylaws or rules, then, after notice and hearing as set 39 forth in the bylaws, all rights, privileges, and benefits conferred by 40 this compact on the defaulting state shall be suspended from the 41 effective date of default as fixed by the commission. 42 (b) The grounds for default include failure of a compacting state



2020

1 to perform its obligations or responsibilities, and any other 2 grounds designated in commission rules. 3 (c) The commission shall immediately notify the defaulting state 4 in writing of the suspension, pending cure of the default. The 5 commission shall stipulate the conditions and the time period 6 within which the defaulting state shall cure the state's default. 7 (d) If the defaulting state fails to cure the default within the time 8 period specified by the commission, the defaulting state shall be 9 expelled from the compact and all rights, privileges, and benefits 10 conferred by the compact shall be terminated from the effective 11 date of the expulsion. 12 (e) Any state that is expelled from the compact shall be liable for 13 any cure prize or prizes for three (3) years after the state's 14 removal. The commission shall also take appropriate legal action 15 to ensure that any compacting state that withdraws from the 16 compact remains liable for paying the state's responsibility toward 17 a prize for a cure that was accepted while the compacting state was 18 a member of the commission. 19 (f) The expelled state must reenact the compact in order to 20 become a compacting state. 21 Sec. 3. (a) The compact dissolves effective upon the date of 22 either of the following: 23 (1) The withdrawal or expulsion of a compacting state, which 24 the withdrawal or expulsion reduces membership in the 25 compact to one (1) compacting state. 26 (2) The commission votes to dissolve the compact. 27 (b) Upon the dissolution of the compact: 28 (1) the compact becomes null and void and shall be of no 29 further force or effect; and 30 (2) the business and affairs of the commission shall be wound 31 up and any surplus funds shall be distributed in accordance 32 with the commission's bylaws. 33 However, the commission shall pay all outstanding prizes awarded 34 before the dissolution of the compact, as well as any other 35 outstanding debts and obligations incurred during the existence of 36 the compact. Any unawarded funds donated to be a part of a prize 37 shall be returned to the donor, along with any interest earned on 38 the amount. 39 **Chapter 15. Severability and Construction** 40 Sec. 1. The provisions of the compact shall be severable. If any 41 phrase, clause, sentence, or provision is deemed unenforceable, the 42 remaining provisions of the compact shall be enforceable.



1 Sec. 2. The provisions of the compact shall be liberally 2 construed to effectuate the compact's purposes. 3 **Chapter 16. Binding Effect of Compact and Other Laws** 4 Sec. 1. Except as provided in section 2(b) of this chapter, nothing 5 in this article prevents the enforcement of any other law of a 6 compacting state. 7 Sec. 2. (a) All lawful actions of the commission, including all 8 commission rules, are binding upon the compacting states. 9 (b) All agreements between the commission and the compacting 10 states are binding in accordance with the compact's terms. 11 (c) Except to the extent authorized by the compacting state's 12 constitution or, if constitutional authorization is not required, by 13 other law of the compacting state, the state, by entering into the 14 compact does not: 15 (1) commit the full faith and credit or taxing power of the 16 compacting state for the payment of prizes or other 17 obligations under the compact; and 18 (2) make prize payment responsibilities or other obligations 19 under the compact a debt of the compacting state. 20 (d) Upon the request of a party to a conflict over the meaning or 21 interpretation of commission actions, and upon a majority vote of 22 the compacting states, the commission may issue advisory opinions 23 regarding the meaning or interpretation in dispute. 24 (e) In the event any provision of the compact exceeds the 25 constitutional limits imposed on any compacting state, the 26 obligations, duties, powers, or jurisdiction sought to be conferred 27 by that provision upon the commission shall be ineffective as to 28 that compacting state, and those obligations, duties, powers, or 29 jurisdiction shall remain in the compacting state and shall be 30 exercised by the agency to which those obligations, duties, powers, 31 or jurisdiction are delegated by law in effect at the time the 32 compact becomes effective. 33 SECTION 7. IC 34-30-2-83.9 IS ADDED TO THE INDIANA 34 CODE AS A NEW SECTION TO READ AS FOLLOWS 35 [EFFECTIVE JULY 1, 2020]: Sec. 83.9. IC 16-46.5-12-1 (Concerning 36 members, officers, executive director, employees, and 37 representatives of the solemn covenant of states commission).

